Repurposing Two Old Friends to Fight Cancer: Caffeine and Statins Journal Articles

abstract

• AbstractStatins are a class of cholesterol-lowering drugs that inhibit 3-hydroxy-3-methylglutaryl-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. Evidence suggests that certain cancers depend on the mevalonate pathway for growth and survival, and thus blocking the mevalonate pathway with statins may offer a viable therapeutic approach for treating cancer, or at least enhance the efficacy of existing cancer drugs. In this issue of Cancer Research, Tran and colleagues showed that caffeine works jointly with FOXM1 inhibition to enhance the antitumor activity of statins in neuroblastoma cells. They found that caffeine synergizes with statins by suppressing statin-induced feedback activation of the mevalonate pathway. Here, we reflect on the potential of combining caffeine and statin drugs as a strategy for potentiating anticancer activity.See related article by Tran et al., p. 2248

authors

• Stouth, Derek W
• Lebeau, Paul F
• Austin, Richard C

status

• published 

publication date

• July 5, 2023

has subject area

• 1112 Oncology and Carcinogenesis (FoR)
• Caffeine (MeSH)
• Dietary Supplements (MeSH)
• Drug Repositioning (MeSH)
• Forkhead Box Protein M1 (MeSH)
• Friends (MeSH)
• Humans (MeSH)
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (MeSH)
• Mevalonic Acid (MeSH)
• Neuroblastoma (MeSH)
• Oncology & Carcinogenesis (Science Metrix)

published in

• Cancer Research  Journal

keywords

• Caffeine
• Dietary Supplements
• Drug Repositioning
• Forkhead Box Protein M1
• Friends
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Mevalonic Acid
• Neuroblastoma

Digital Object Identifier (DOI)

• 10.1158/0008-5472.can-23-1066

PubMed ID

• 37403629

start page

• 2091

end page

• 2092

volume

• 83

issue

• 13